Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Senti Biosciences Inc (SNTI)

Senti Biosciences Inc (SNTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,561
  • Shares Outstanding, K 45,755
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -71,060 K
  • 60-Month Beta 2.88
  • Price/Sales 6.27
  • Price/Cash Flow N/A
  • Price/Book 0.29
Trade SNTI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.51
  • Most Recent Earnings $-0.26 on 05/09/24
  • Next Earnings Date 05/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +237,957.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2750 +23.67%
on 04/25/24
0.4380 -22.35%
on 04/30/24
+0.0592 (+21.08%)
since 04/24/24
3-Month
0.2710 +25.50%
on 04/22/24
0.5100 -33.31%
on 03/20/24
-0.0700 (-17.07%)
since 02/23/24
52-Week
0.2701 +25.92%
on 10/27/23
1.1000 -69.08%
on 06/14/23
-0.6203 (-64.59%)
since 05/24/23

Most Recent Stories

More News
Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm The Briscoe Law Firm, PLLC are investigating potential violation of laws in connection...

BBAI : 1.5700 (+3.29%)
SNTI : 0.3401 (-3.11%)
TNGX : 6.91 (-2.54%)
BOXD : 0.1898 (-15.27%)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dynamics Special Purpose Corp., which merged with Senti Bioscience, Inc. ("Senti"...

SNTI : 0.3401 (-3.11%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 1.0900 (+2.83%)
ONC.TO : 1.52 (+2.01%)
SNTI : 0.3401 (-3.11%)
INBX : 34.14 (-0.15%)
IMVT : 28.95 (+1.97%)
AUTL : 3.92 (+1.29%)
BMY : 41.24 (-0.72%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

BMY : 41.24 (-0.72%)
ONC.TO : 1.52 (+2.01%)
ONCY : 1.0900 (+2.83%)
SNTI : 0.3401 (-3.11%)
INBX : 34.14 (-0.15%)
IMVT : 28.95 (+1.97%)
AUTL : 3.92 (+1.29%)
Chardan Announces Launch of ChEF (Chardan Equity Facility)

/PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution...

SNTI : 0.3401 (-3.11%)
CNTQ : 14.00 (-8.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Senti Biosciences Inc. is a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. Senti Biosciences Inc., formerly known as Dynamics Special Purpose Corp., is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 0.4168
2nd Resistance Point 0.3903
1st Resistance Point 0.3652
Last Price 0.3401
1st Support Level 0.3136
2nd Support Level 0.2871
3rd Support Level 0.2620

See More

52-Week High 1.1000
Fibonacci 61.8% 0.7830
Fibonacci 50% 0.6851
Fibonacci 38.2% 0.5871
Last Price 0.3401
52-Week Low 0.2701

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar